STOCK TITAN

BioStem Technologies (BSEM) director discloses 7,671 RSUs vesting in 2026

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

BioStem Technologies director Mark A. Glickman reported his initial equity position as a company insider. He holds 7,671 Restricted Stock Units, each representing a contingent right to receive one share of BioStem’s common stock. These RSUs vest on August 27, 2026, and are held directly.

Positive

  • None.

Negative

  • None.
Insider Glickman Mark A
Role Director
Type Security Shares Price Value
holding Restricted Stock Units F2, F1 -- -- --
Holdings After Transaction: Restricted Stock Units — 7,671 shares (Direct)
Footnotes (2)
  1. F1. These restricted stock units vest on August 27, 2026.
  2. F2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Restricted Stock Units held 7,671 units RSUs held directly by director Mark A. Glickman as reported on Form 3
Underlying common shares 7,671 shares Each RSU represents a contingent right to receive one share of common stock
RSU vesting date August 27, 2026 Vesting date for the reported 7,671 Restricted Stock Units
Restricted Stock Units financial
"These restricted stock units vest on August 27, 2026."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
beneficial ownership financial
"reported his initial equity position as a company insider and beneficial owner"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider position did Mark A. Glickman report at BioStem Technologies (BSEM)?

Mark A. Glickman, a director of BioStem Technologies, reported beneficial ownership of 7,671 Restricted Stock Units. These RSUs are linked to the company’s common stock and are reported as directly held equity-based compensation.

How many Restricted Stock Units does the BSEM director hold according to the Form 3?

The director holds 7,671 Restricted Stock Units. Each unit corresponds to a contingent right to receive one share of BioStem Technologies’ common stock, providing potential future share ownership once vesting conditions are satisfied.

When do Mark A. Glickman’s BioStem Technologies (BSEM) RSUs vest?

The reported Restricted Stock Units vest on August 27, 2026. Vesting is the date when the director earns the right to receive the underlying BioStem common shares associated with these equity awards, subject to the plan’s terms.

What does each Restricted Stock Unit represent for BioStem Technologies (BSEM) director Glickman?

Each Restricted Stock Unit represents a contingent right to receive one share of BioStem Technologies’ common stock. Actual share delivery typically occurs after the vesting date and any additional conditions in the equity plan are met.

Is the BSEM director’s RSU ownership reported as direct or indirect?

The Form 3 reports the 7,671 Restricted Stock Units as held under direct ownership. This indicates the director himself is the beneficial owner of these RSUs, rather than holding them through an intermediary entity or trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Glickman Mark A

(Last)(First)(Middle)
C/O BIOSTEM TECHNOLOGIES, INC.
2836 CENTER PORT CIRCLE

(Street)
POMPANO BEACH FLORIDA 33064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026
3. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units (1) (1)Common Stock7,671(2)D
Explanation of Responses:
1. These restricted stock units vest on August 27, 2026.
2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
/s/ Mark Glickman08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)